Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Institute of Drug Research, School of Pharmacy-Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
J Control Release. 2018 Jun 10;279:1-7. doi: 10.1016/j.jconrel.2018.04.010. Epub 2018 Apr 11.
The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.
研究了与紫杉醇联合应用促进剂药物对增加紫杉醇抗肿瘤效果的影响。患有原位 4T1-Luc 乳腺癌的小鼠接受了紫杉醇和特定促进剂药物的单一肿瘤内注射。评估了几种促进剂药物，包括：地塞米松、氯沙坦、烟酰胺、氮酮和油酸。地塞米松以剂量依赖性方式对紫杉醇的抗肿瘤活性表现出最高的效果。然而，这种效果伴随着地塞米松的全身作用，并且无法防止肿瘤转移到肺部。局部联合应用促进剂药物与抗癌药物可以增强它们的抗肿瘤作用。需要进一步研究以确定促进剂和抗癌药物的最有效组合，以及它们是否适合乳腺癌疾病的临床管理。
